Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sana Biotechnology, Inc. - Common Stock (NQ:SANA)

3.415 +0.085 (+2.55%)
Streaming Delayed Price Updated: 11:29 AM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sana Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Sana Biotechnology, Inc. Stockholder News: Robbins LLP Reminds Investors of the Class Action Lawsuit Against SANA
From Robbins LLP
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
From Pomerantz LLP
Via GlobeNewswire
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
 
Via Benzinga
Rosen Law Firm Urges Sana Biotechnology, Inc. (NASDAQ: SANA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts. 
Via Stocktwits
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025. 
Via MarketBeat
Topics ETFs Economy
Biotech Breakthroughs: Sana Biotechnology (NASDAQ: SANA) Type 1 Diabetes, CS Diagnostics (OTCQB: CSDX) Cancer Therapy – CURR, TPET, PRSO, PNPN.V, EONR – Plus More Stocks Under $2 Inside See Now!
Via AB Newswire
Topics Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Crude Oil Down 1%; US Weekly Jobless Claims Decline
 
Via Benzinga
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
US Stocks Down; Acuity Brands Posts Weak Revenue
 
Via Benzinga
Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why
Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes without immunosuppression. 
Via Benzinga
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at December 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Topics Artificial Intelligence
Sana Biotechnology to Present at September 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
From Sana Biotechnology, Inc
Via GlobeNewswire
SANA Stock Earnings: Sana Biotechnology Misses EPS for Q2 2024
SANA stock results show that Sana Biotechnology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.